Global Mesna Injection Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Mesna Injection Market Research Report 2024
Mesna injection is indicated for the prevention of urinary tract toxicity caused by oxazaphosphrine drugs (including ifosfamide, cyclophosphamide, and trophasfamide). Mesna should be used concomitantly with ifosfamide in the chemotherapy of tumors. When high-dose cyclophosphamide (greater than 10 mg/kg) and trophasfamide are used, mesna should be used in combination.
According to Mr Accuracy reports’s new survey, global Mesna Injection market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mesna Injection market research.
Key manufacturers engaged in the Mesna Injection industry include Baxter, Cadila Healthcare, Mylan, Teva Pharmaceutical, Fresenius Kabi, Hikma Pharmaceuticals, Gland Pharma, Sagent Pharmaceuticals and Athenex, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Mesna Injection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Mesna Injection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Mesna Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Baxter
Cadila Healthcare
Mylan
Teva Pharmaceutical
Fresenius Kabi
Hikma Pharmaceuticals
Gland Pharma
Sagent Pharmaceuticals
Athenex
Jiangsu Hengrui Medicine
Sinopharm A-Think Pharmaceutical
Segment by Type
High Dose
Low Dose
Hospital
Pharmacy
Others
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Mesna Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports’s new survey, global Mesna Injection market is projected to reach US$ million in 2034, increasing from US$ million in 2022, with the CAGR of % during the period of 2024 to 2034. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Mesna Injection market research.
Key manufacturers engaged in the Mesna Injection industry include Baxter, Cadila Healthcare, Mylan, Teva Pharmaceutical, Fresenius Kabi, Hikma Pharmaceuticals, Gland Pharma, Sagent Pharmaceuticals and Athenex, etc. Among those manufacturers, the top 3 players guaranteed % supply worldwide in 2022.
When refers to consumption region, % volume of Mesna Injection were sold to North America, Europe and Asia Pacific in 2022. Moreover, China, plays a key role in the whole Mesna Injection market and estimated to attract more attentions from industry insiders and investors.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Mesna Injection market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Baxter
Cadila Healthcare
Mylan
Teva Pharmaceutical
Fresenius Kabi
Hikma Pharmaceuticals
Gland Pharma
Sagent Pharmaceuticals
Athenex
Jiangsu Hengrui Medicine
Sinopharm A-Think Pharmaceutical
Segment by Type
High Dose
Low Dose
Segment by Application
Hospital
Pharmacy
Others
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Mesna Injection report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source